Lucid Diagnostics’ (LUCD) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD) in a research note published on Wednesday morning,Benzinga reports. The brokerage currently has a $3.00 target price on the stock.

Other research analysts have also issued research reports about the stock. Ascendiant Capital Markets lifted their price objective on shares of Lucid Diagnostics from $7.00 to $7.50 and gave the stock a “buy” rating in a research note on Monday, April 21st. BTIG Research set a $2.00 price target on shares of Lucid Diagnostics in a research note on Tuesday, March 25th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $2.00 target price on shares of Lucid Diagnostics in a research note on Wednesday, March 26th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Lucid Diagnostics currently has an average rating of “Buy” and an average target price of $3.50.

Lucid Diagnostics Stock Up 2.4%

Shares of NASDAQ:LUCD opened at $1.26 on Wednesday. The firm has a market cap of $132.78 million, a P/E ratio of -1.11 and a beta of 1.28. Lucid Diagnostics has a 12 month low of $0.68 and a 12 month high of $1.80. The company’s 50-day moving average price is $1.35 and its two-hundred day moving average price is $1.13.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in LUCD. Alyeska Investment Group L.P. acquired a new stake in shares of Lucid Diagnostics during the 1st quarter worth $2,813,000. Sargent Investment Group LLC acquired a new stake in shares of Lucid Diagnostics during the fourth quarter valued at about $442,000. Ghisallo Capital Management LLC acquired a new stake in shares of Lucid Diagnostics during the first quarter valued at about $629,000. Geode Capital Management LLC boosted its stake in shares of Lucid Diagnostics by 30.9% during the fourth quarter. Geode Capital Management LLC now owns 279,504 shares of the company’s stock valued at $229,000 after purchasing an additional 65,964 shares in the last quarter. Finally, XML Financial LLC acquired a new position in shares of Lucid Diagnostics in the first quarter worth approximately $266,000. Institutional investors own 74.01% of the company’s stock.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.